Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759392 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT03759392 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 276 participants.
The verdict
NCT03759392, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo
Interventions
- DRUG Placebo
- DRUG Omecamtiv Mecarbil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2019-04-09 |
| Est. Completion | 2022-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03759392
The ClinicalTrials.gov registry entry for NCT03759392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03759392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03759392 about?
NCT03759392 is a clinical study titled "Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure". The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo
What is the current status of trial NCT03759392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2019-04-09. Estimated completion is 2022-01-06.
What interventions are being tested in trial NCT03759392?
The interventions under investigation include: Placebo (DRUG), Omecamtiv Mecarbil (DRUG).
Who is sponsoring clinical trial NCT03759392?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.